Behind the rapid growth of orders from wuxi apptec breaking the 'impossible triangle'
It's time for pharmaceutical investors to refocus on CXO fundamentals.
Wuxi Apptec's net income in Q3 was 2.29 billion yuan, a year-on-year decrease of 17.02%. | Financial report news
Wuxi Apptec's third-quarter revenue and net income both declined. The third-quarter revenue was 10.46 billion RMB, a year-on-year decrease of 1.96%, with declines in revenue from major business segments.
Cantor Fitzgerald Reiterates Overweight on Zai Lab
Zai Lab Stock Rockets 24% on Data for Lung Cancer ADC Drug
Zai Lab Shares Are Trading Higher After the Company Presented Data From Its Ongoing Phase 1a/1b Study of ZL-1310 for Previously Treated Extensive-stage Small Cell Lung Cancer at the EORTC-NCI-AACR Symposium 2024.
Indaptus Therapeutics Announces Clinical Supply Agreement With BeiGene To Evaluate Novel Cancer Treatment Combinations
每天都在學習中 :